Prevail Therapeutics Inc. (NASDAQ:PRVL) Given Consensus Rating of “Buy” by Analysts

Shares of Prevail Therapeutics Inc. (NASDAQ:PRVL) have been given an average rating of “Buy” by the six research firms that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have issued a buy recommendation on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $18.33.

Several equities research analysts have recently commented on PRVL shares. BidaskClub downgraded Prevail Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday. Wedbush reissued a “buy” rating and set a $20.00 price target on shares of Prevail Therapeutics in a research report on Friday, November 1st. Cowen reissued a “buy” rating on shares of Prevail Therapeutics in a research report on Tuesday, November 12th. Finally, Zacks Investment Research lowered Prevail Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, January 14th.

Shares of NASDAQ PRVL opened at $17.40 on Friday. Prevail Therapeutics has a 12 month low of $7.41 and a 12 month high of $19.25. The company has a quick ratio of 17.05, a current ratio of 17.05 and a debt-to-equity ratio of 0.06. The business has a fifty day simple moving average of $17.66 and a 200-day simple moving average of $13.45.

Prevail Therapeutics (NASDAQ:PRVL) last announced its earnings results on Tuesday, November 12th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.12). Equities research analysts forecast that Prevail Therapeutics will post -2.74 EPS for the current year.

Large investors have recently bought and sold shares of the stock. Barclays PLC acquired a new position in Prevail Therapeutics during the third quarter valued at $47,000. Fred Alger Management LLC acquired a new position in Prevail Therapeutics during the fourth quarter valued at $47,000. Citigroup Inc. raised its position in Prevail Therapeutics by 965.4% during the fourth quarter. Citigroup Inc. now owns 4,123 shares of the company’s stock valued at $65,000 after buying an additional 3,736 shares during the period. Tower Research Capital LLC TRC acquired a new position in Prevail Therapeutics during the fourth quarter valued at $67,000. Finally, California State Teachers Retirement System acquired a new position in Prevail Therapeutics during the third quarter valued at $142,000. 78.00% of the stock is currently owned by hedge funds and other institutional investors.

Prevail Therapeutics Company Profile

Prevail Therapeutics Inc, a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. The company's lead product candidate is PR001 for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease.

Recommended Story: Mutual Funds

Receive News & Ratings for Prevail Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prevail Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply